Ahmad Sahil, Gupta Sudheer, Kumar Rahul, Varshney Grish C, Raghava Gajendra P S
1] CSIR-Institute of Microbial Technology Chandigarh, India [2].
CSIR-Institute of Microbial Technology Chandigarh, India.
Sci Rep. 2014 Mar 27;4:4483. doi: 10.1038/srep04483.
Monoclonal antibody Trastuzumab/Herceptin is considered as frontline therapy for Her2-positive breast cancer patients. However, it is not effective against several patients due to acquired or de novo resistance. In last one decade, several assays have been performed to understand the mechanism of Herceptin resistance with/without supplementary drugs. This manuscript describes a database HerceptinR, developed for understanding the mechanism of resistance at genetic level. HerceptinR maintains information about 2500 assays performed against various breast cancer cell lines (BCCs), for improving sensitivity of Herceptin with or without supplementary drugs. In order to understand Herceptin resistance at genetic level, we integrated genomic data of BCCs that include expression, mutations and copy number variations in different cell lines. HerceptinR will play a vital role in i) designing biomarkers to identify patients eligible for Herceptin treatment and ii) identification of appropriate supplementary drug for a particular patient. HerceptinR is available at http://crdd.osdd.net/raghava/herceptinr/.
单克隆抗体曲妥珠单抗/赫赛汀被视为Her2阳性乳腺癌患者的一线治疗药物。然而，由于获得性或原发性耐药，它对部分患者无效。在过去十年中，已经进行了多项试验，以了解使用或不使用辅助药物时赫赛汀耐药的机制。本手稿描述了一个名为HerceptinR的数据库，该数据库旨在从基因层面了解耐药机制。HerceptinR保存了针对各种乳腺癌细胞系（BCC）进行的2500项试验的信息，用于提高使用或不使用辅助药物时赫赛汀的敏感性。为了从基因层面了解赫赛汀耐药性，我们整合了乳腺癌细胞系的基因组数据，这些数据包括不同细胞系中的表达、突变和拷贝数变异。HerceptinR将在以下方面发挥重要作用：i）设计生物标志物以识别适合接受赫赛汀治疗的患者，ii）为特定患者识别合适的辅助药物。可通过http://crdd.osdd.net/raghava/herceptinr/访问HerceptinR。
